

10. REFERENCES

1. Boland CR, Sinicrope FA, Brenner DE, Carethers JM. Colorectal cancer prevention and treatment. *Gastroenterology* 2000;**118**:S115-28.
2. Whitehouse A, Meredith DM, Markham AF. DNA mismatch repair genes and their association with colorectal cancer. *Int J Mol Med* 1998;**1**:469-74.
3. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. *Cell* 1990;**61**:759-67.
4. Goel A, Arnold CN, Boland CR. Multistep progression of colorectal cancer in the setting of microsatellite instability: new details and novel insights. *Gastroenterology* 2001;**121**:1497-502.
5. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. *Cell* 2002;**108**:153-64.
6. Hickman JA. Apoptosis induced by anticancer drugs. *Cancer Metastasis Rev* 1992;**11**:121-39.
7. Fisher DE. Apoptosis in cancer therapy: crossing the threshold. *Cell* 1994;**78**:539-42.
8. Makin G, Hickman JA. Apoptosis and cancer chemotherapy. *Cell Tissue Res* 2000;**301**:143-52.
9. Martinou JC, Green DR. Breaking the mitochondrial barrier. *Nat Rev Mol Cell Biol* 2001;**2**:63-7.
10. Gross A, McDonnell JM, Korsmeyer SJ. BCL-2 family members and the mitochondria in apoptosis. *Genes Dev* 1999;**13**:1899-911.
11. Kluck RM, Bossy-Wetzler E, Green DR, Newmeyer DD. The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. *Science* 1997;**275**:1132-6.
12. Rao L, Perez D, White E. Lamin proteolysis facilitates nuclear events during apoptosis. *J Cell Biol* 1996;**135**:1441-55.
13. Kamesaki S, Kamesaki H, Jorgensen TJ, Tanizawa A, Pommier Y, Cossman J. Bcl-2 protein inhibits etoposide-induced apoptosis through its effects on events

subsequent to topoisomerase II-induced DNA strand breaks and their repair. *Cancer Res* 1993;**53**:4251-6.

14. Miyashita T, Reed JC. Bcl-2 gene transfer increases relative resistance of S49.1 and WEHI7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. *Cancer Res* 1992;**52**:5407-11.

15. Walton MI, Whyson D, O'Connor PM, Hockenbery D, Korsmeyer SJ, Kohn KW. Constitutive expression of human Bcl-2 modulates nitrogen mustard and camptothecin induced apoptosis. *Cancer Res* 1993;**53**:1853-61.

16. Schmitt E, Cimoli G, Steyaert A, Bertrand R. Bcl-xL modulates apoptosis induced by anticancer drugs and delays DEVDase and DNA fragmentation-promoting activities. *Exp Cell Res* 1998;**240**:107-21.

17. Simonian PL, Grillot DA, Nunez G. Bcl-2 and Bcl-XL can differentially block chemotherapy-induced cell death. *Blood* 1997;**90**:1208-16.

18. Jones NA, Turner J, McIlwrath AJ, Brown R, Dive C. Cisplatin- and paclitaxel-induced apoptosis of ovarian carcinoma cells and the relationship between bax and bak up-regulation and the functional status of p53. *Mol Pharmacol* 1998;**53**:819-26.

19. Guo B, Cao S, Toth K, Azrak RG, Rustum YM. Overexpression of Bax enhances antitumor activity of chemotherapeutic agents in human head and neck squamous cell carcinoma. *Clin Cancer Res* 2000;**6**:718-24.

20. Hartwell LH, Weinert TA. Checkpoints: controls that ensure the order of cell cycle events. *Science* 1989;**246**:629-34.

21. Elledge SJ. Cell cycle checkpoints: preventing an identity crisis. *Science* 1996;**274**:1664-71.

22. Sherr CJ. Cancer cell cycles. *Science* 1996;**274**:1672-77.

23. Roovers K, Assoian RK. Integrating the MAP kinase signal into the G1 phase cell cycle machinery. *Bioessays* 2000;**22**:818-26.

24. Agami R, Bernards R. Convergence of mitogenic and DNA damage signaling in the G1 phase of the cell cycle. *Cancer Lett* 2002;**177**:111-8.

25. Di Leonardo A, Linke SP, Clarkin K, Wahl GM. DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of Cip1 in normal human fibroblasts. *Genes Dev* 1994;**8**:2540-51.
26. O'Connell MJ, Walworth NC, Carr AM. The G2-phase DNA-damage checkpoint. *Trends Cell Biol* 2000;**10**:296-303.
27. Morgan DO. Principles of CDK regulation. *Nature* 1995;**374**:131-34.
28. Draetta G, Luca F, Westendorf J, Brizuela L, Ruderman J, Beach D. Cdc2 protein kinase is complexed with both cyclin A and B: evidence for proteolytic inactivation of MPF. *Cell* 1989;**56**:829-38.
29. Smits VA, Medema RH. Checking out the G(2)/M transition. *Biochim Biophys Acta* 2001;**1519**:1-12.
30. Liu F, Stanton JJ, Wu Z, Piwnica-Worms H. The human Myt1 kinase preferentially phosphorylates Cdc2 on Threonine 14 and localizes to the endoplasmic reticulum and Golgi complex. *Mol Cell Biol* 1997;**17**:571-83.
31. Parker LL, Atherton-Fessler S, Piwnica-Worms H. p107^{wee1} is a dual-specificity kinase that phosphorylates p34^{cdc2} on tyrosine 15. *Proc Natl Acad Sci U S A* 1992;**89**:2917-21.
32. Parker LL, P-W, H. Inactivation of the p34^{cdc2}-Cyclin B complex by the human WEE1 tyrosine kinase. *Science* 1992;**257**:1955-57.
33. McGowan CH, P. Human Wee 1 kinase inhibits cell division by phosphorylating p34^{cdc2} exclusively on Tyr15. *EMBO J* 1993;**12**:75-85.
34. Lee MS, Ogg S, Xu M, Parker LL, Donoghue DJ, Maller JL, Piwnica-Worms H. cdc25+ encodes a protein phosphatase that dephosphorylates p34cdc2. *Mol Biol Cell* 1992;**3**:73-84.
35. Kumagai A, Dunphy WG. The cdc25 protein controls tyrosine dephosphorylation of the cdc2 protein in a cell-free system. *Cell* 1991;**64**:903-14.
36. Brown AL, Lee CH, Schwarz JK, Mitiku N, Piwnica-Worms H, Chung JH. A human Cds1-related kinase that functions downstream of ATM protein in the cellular response to DNA damage. *Proc Natl Acad Sci U S A* 1999;**96**:3745-50.
37. Liu Q, Guntuku S, Cui XS, Matsuoka S, Cortez D, Tamai K, Luo G, Carattini-Rivera S, DeMayo F, Bradley A, Donehower LA, Elledge SJ. Chk1 is an

essential kinase that is regulated by Atr and required for the G₂/M DNA damage checkpoint. *Genes Dev* 2000;**14**:1448-59.

38. Matsuoka S, Huang M, Elledge SJ. Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. *Science* 1998;**282**:1893-7.

39. Furnari B, Blasina A, Boddy MN, McGowan CH, Russell P. Cdc25 inhibited in vivo and in vitro by checkpoint kinases Cds1 and Chk1. *Mol Biol Cell* 1999;**10**:833-45.

40. Zeng Y, Forbes KC, Wu Z, Moreno S, Piwnica-Worms H, Enoch T. Replication checkpoint requires phosphorylation of the phosphatase Cdc25 by Cds1 or Chk1. *Nature* 1998;**395**:507-10.

41. Peng C-Y, Graves PR, Thoma RS, Wu Z, Shaw AS, Piwnica-Worms H. Mitotic and G₂ checkpoint control: regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216. *Science* 1997;**277**:1501-05.

42. Zeng Y, Piwnica-Worms H. DNA damage and replication checkpoints in fission yeast require nuclear exclusion of the Cdc25 phosphatase via 14-3-3 binding. *Mol Cell Biol* 1999;**19**:7410-9.

43. Taylor WR, Stark GR. Regulation of the G₂/M transition by p53. *Oncogene* 2001;**20**:1803-15.

44. Waldman T, Kinzler KW, Vogelstein B. p21 is necessary for the p53-mediated G₁ arrest in human cancer cells. *Cancer Res* 1995;**55**:5187-90.

45. Hermeking H, Lengauer C, Polyak K, He TC, Zhang L, Thiagalingam S, Kinzler KW, Vogelstein B. 14-3-3 sigma is a p53-regulated inhibitor of G₂/M progression. *Mol Cell* 1997;**1**:3-11.

46. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. *Nature* 2000;**408**:307-10.

47. Medema RH, Klompaker R, Smits VA, Rijksen G. p21waf1 can block cells at two points in the cell cycle, but does not interfere with processive DNA-replication or stress-activated kinases. *Oncogene* 1998;**16**:431-41.

48. Taylor WR, DePrimo SE, Agarwal A, Agarwal ML, Schonthal AH, Katula KS, Stark GR. Mechanisms of G₂ arrest in response to overexpression of p53. *Mol Biol Cell* 1999;**10**:3607-22.

49. Smits VA, Klompmaker R, Vallenius T, Rijksen G, Makela TP, Medema RH. p21 inhibits Thr161 phosphorylation of Cdc2 to enforce the G2 DNA damage checkpoint. *J Biol Chem* 2000;**275**:30638-43.
50. Chan TA, Hermeking H, Lengauer C, Kinzler KW, Vogelstein B. 14-3-3Sigma is required to prevent mitotic catastrophe after DNA damage. *Nature* 1999;**401**:616-20.
51. Waldman T, Lengauer C, Kinzler KW, Vogelstein B. Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. *Nature* 1996;**381**:713-6.
52. Roninson IB, Broude EV, Chang BD. If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells. *Drug Resist Updat* 2001;**4**:303-13.
53. Hirao A, Kong YY, Matsuoka S, Wakeham A, Ruland J, Yoshida H, Liu D, Elledge SJ, Mak TW. DNA damage-induced activation of p53 by the checkpoint kinase Chk2. *Science* 2000;**287**:1824-7.
54. Shieh SY, Ahn J, Tamai K, Taya Y, Prives C. The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. *Genes Dev* 2000;**14**:289-300.
55. Vousden KH. Activation of the p53 tumor suppressor protein. *Biochim Biophys Acta* 2002;**1602**:47-59.
56. Abraham RT. Cell cycle checkpoint signaling through the ATM and ATR kinases. *Genes Dev* 2001;**15**:2177-96.
57. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. *Cell* 1995;**80**:293-9.
58. Bartke T, Siegmund D, Peters N, Reichwein M, Henkler F, Scheurich P, Wajant H. p53 upregulates cFLIP, inhibits transcription of NF-kappaB-regulated genes and induces caspase-8-independent cell death in DLD-1 cells. *Oncogene* 2001;**20**:571-80.
59. Hoffman WH, Biade S, Zilfou JT, Chen J, Murphy M. Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. *J Biol Chem* 2002;**277**:3247-57.

60. Ryan KM, Phillips AC, Vousden KH. Regulation and function of the p53 tumor suppressor protein. *Curr Opin Cell Biol* 2001;**13**:332-7.
61. Wu Y, Mehew JW, Heckman CA, Arcinas M, Boxer LM. Negative regulation of bcl-2 expression by p53 in hematopoietic cells. *Oncogene* 2001;**20**:240-51.
62. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE, Jacks T. p53 status and the efficacy of cancer therapy in vivo. *Science* 1994;**266**:807-10.
63. Wahl AF, Donaldson KL, Fairchild C, Lee FY, Foster SA, Demers GW, Galloway DA. Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. *Nat Med* 1996;**2**:72-9.
64. Hawkins DS, Demers GW, Galloway DA. Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. *Cancer Res* 1996;**56**:892-8.
65. Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L, Williams J, Lengauer C, Kinzler KW, Vogelstein B. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. *J Clin Invest* 1999;**104**:263-9.
66. Mueller H, Eppenberger U. The dual role of mutant p53 protein in chemosensitivity of human cancers. *Anticancer Res* 1996;**16**:3845-8.
67. Bellacosa A. Functional interactions and signaling properties of mammalian DNA mismatch repair proteins. *Cell Death Differ* 2001;**8**:1076-92.
68. Jiricny J, Nystrom-Lahti M. Mismatch repair defects in cancer. *Curr Opin Genet Dev* 2000;**10**:157-61.
69. Li GM. The role of mismatch repair in DNA damage-induced apoptosis. *Oncol Res* 1999;**11**:393-400.
70. Lan Z, Sever-Chroneos Z, Strobeck MW, Park CH, Baskaran R, Edelmann W, Leone G, Knudsen ES. DNA damage invokes mismatch repair-dependent cyclin D1 attenuation and retinoblastoma signaling pathways to inhibit CDK2. *J Biol Chem* 2002;**277**:8372-81.
71. Carethers JM, Hawn MT, Chauhan DP, Luce MC, Marra G, Koi M, Boland CR. Competency in mismatch repair prohibits clonal expansion of cancer cells treated with N-methyl-N'-nitro-N-nitrosoguanidine. *J Clin Invest* 1996;**98**:199-206.

72. Hawn MT, Umar A, Carethers JM, Marra G, Kunkel TA, Boland CR, Koi M. Evidence for a connection between the mismatch repair system and the G2 cell cycle checkpoint. *Cancer Res* 1995;**55**:3721-5.
73. Sedwick WD, Markowitz SD, Veigl ML. Mismatch repair and drug responses in cancer. *Drug Resist Updat* 1999;**2**:295-306.
74. Carethers JM, Chauhan DP, Fink D, Nebel S, Bresalier RS, Howell SB, Boland CR. Mismatch repair proficiency and in vitro response to 5-fluorouracil. *Gastroenterology* 1999;**117**:123-31.
75. Gong JG, Costanzo A, Yang HQ, Melino G, Kaelin WG, Jr., Levrero M, Wang JY. The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. *Nature* 1999;**399**:806-9.
76. Fiumicino S, Martinelli S, Colussi C, Aquilina G, Leonetti C, Crescenzi M, Bignami M. Sensitivity to DNA cross-linking chemotherapeutic agents in mismatch repair-defective cells in vitro and in xenografts. *Int J Cancer* 2000;**85**:590-6.
77. Takahashi I, Kobayashi E, Asano K, Yoshida M, Nakano H. UCN-01, a selective inhibitor of protein kinase C from *Streptomyces*. *J Antibiot* 1987;**40**:1782-4.
78. Akinaga S, Nomura K, Gomi K, Okabe M. Enhancement of antitumor activity of mitomycin C in vitro and in vivo by UCN-01, a selective inhibitor of protein kinase C. *Cancer Chemother Pharmacol* 1993;**32**:183-9.
79. Sugiyama K, Shimizu M, Akiyama T, Tamaoki T, Yamaguchi K, Takahashi R, Eastman A, Akinaga S. UCN-01 selectively enhances mitomycin C cytotoxicity in p53 defective cells which is mediated through S and/or G(2) checkpoint abrogation. *Int J Cancer* 2000;**85**:703-9.
80. Bunch RT, Eastman A. Enhancement of cisplatin-induced cytotoxicity by 7-hydroxystaurosporine (UCN-01), a new G2-checkpoint inhibitor. *Clin Cancer Res* 1996;**2**:791-7.
81. Husain A, Yan XJ, Rosales N, Aghajanian C, Schwartz GK, Spriggs DR. UCN-01 in ovary cancer cells: effective as a single agent and in combination with cis-diamminedichloroplatinum(II) independent of p53 status. *Clin Cancer Res* 1997;**3**:2089-97.

82. Pollack IF, Kawecki S, Lazo JS. Blocking of glioma proliferation in vitro and in vivo and potentiating the effects of BCNU and cisplatin: UCN-01, a selective protein kinase C inhibitor. *J Neurosurg* 1996;**84**:1024-32.
83. Lee SI, Brown MK, Eastman A. Comparison of the efficacy of 7-hydroxystaurosporine (UCN-01) and other staurosporine analogs to abrogate cisplatin-induced cell cycle arrest in human breast cancer cell lines. *Biochem Pharmacol* 1999;**58**:1713-21.
84. Hu B, Zhou XY, Wang X, Zeng ZC, Iliakis G, Wang Y. The radioresistance to killing of A1-5 cells derives from activation of the Chk1 pathway. *J Biol Chem* 2001;**276**:17693-8.
85. Wang Q, Fan S, Eastman A, Worland PJ, Sausville EA, O'Connor PM. UCN-01: a potent abrogator of G₂ checkpoint function in cancer cells with disrupted p53. *J Natl Cancer Inst* 1996;**88**:956-65.
86. Jones CB, Clements MK, Wasi S, Daoud SS. Enhancement of camptothecin-induced cytotoxicity with UCN-01 in breast cancer cells: abrogation of S/G₂ arrest. *Cancer Chemother Pharmacol* 2000;**45**:252-8.
87. Shao RG, Shimizu T, Pommier Y. 7-Hydroxystaurosporine (UCN-01) induces apoptosis in human colon carcinoma and leukemia cells independently of p53. *Exp Cell Res* 1997;**234**:388-97.
88. Abe S, Kubota T, Otani Y, Furukawa T, Watanabe M, Kumai K, Kitajima M. UCN-01 (7-hydroxystaurosporine) enhances 5-fluorouracil cytotoxicity through down-regulation of thymidylate synthetase messenger RNA. *Jpn J Cancer Res* 2000;**91**:1192-98.
89. Goekjian PG, Jirousek MR. Protein kinase C inhibitors as novel anticancer drugs. *Expert Opin Investig Drugs* 2001;**10**:2117-40.
90. Bunch RT, Eastman A. 7-Hydroxystaurosporine (UCN-01) causes redistribution of proliferating cell nuclear antigen and abrogates cisplatin-induced S-phase arrest in Chinese hamster ovary cells. *Cell Growth Differ* 1997;**8**:779-88.
91. Powell SN, DeFrank JS, Connell P, Eogan M, Preffer F, Dombkowski D, Tang W, Friend S. Differential sensitivity of p53(-) and p53(+) cells to caffeine-induced radiosensitization and override of G₂ delay. *Cancer Res* 1995;**55**:1643-8.

92. Busby EC, Leistriz DF, Abraham RT, Karnitz LM, Sarkaria JN. The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1. *Cancer Res* 2000;**60**:2108-12.
93. Graves PR, Yu L, Schwarz JK, Gales J, Sausville EA, O'Connor PM, Piwnica-Worms H. The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01. *J Biol Chem* 2000;**275**:5600-5.
94. Sarkaria JN, Busby EC, Tibbetts RS, Roos P, Taya Y, Karnitz LM, Abraham RT. Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine. *Cancer Res* 1999;**59**:4375-82.
95. Yu L, Orlandis L, Wang P, Orr MS, Senderowicz AM, Sausville EA, Silvestrini R, Watanabe N, Piwnica-Worms H, O'Connor PM. UCN-01 abrogates G₂ arrest through a Cdc2-dependent pathway that is associated with inactivation of the Wee1Hu kinase and activation of the Cdc25C phosphatase. *J Biol Chem* 1998;**273**:33455-64.
96. Senderowicz AM. Small molecule modulators of cyclin-dependent kinases for cancer therapy. *Oncogene* 2000;**19**:6600-6.
97. Akinaga S, Sugiyama K, Akiyama T. UCN-01 (7-hydroxystaurosporine) and other indolocarbazole compounds: a new generation of anti-cancer agents for the new century? *Anticancer Drug Des* 2000;**15**:43-52.
98. Shao RG, Cao CX, Shimizu T, O'Connor PM, Kohn KW, Pommier Y. Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function. *Cancer Res* 1997;**57**:4029-35.
99. Monks A, Harris ED, Vaigro-Wolff A, Hose CD, Connelly JW, Sausville EA. UCN-01 enhances the in vitro toxicity of clinical agents in human tumor cell lines. *Invest New Drugs* 2000;**18**:95-107.
100. Luo Y, Rockow-Magnone SK, Joseph MK, Bradner J, Butler CC, Tahir SK, Han EK, Ng SC, Severin JM, Gubbins EJ, Reilly RM, Rueter A, Simmer RL, et al. Abrogation of G₂ checkpoint specifically sensitize p53 defective cells to cancer chemotherapeutic agents. *Anticancer Res* 2001;**21**:23-8.

101. Wang Q, Worland PJ, Clark JL, Carlson BA, Sausville EA. Apoptosis in 7-hydroxystaurosporine-treated T lymphoblasts correlates with activation of cyclin-dependent kinases 1 and 2. *Cell Growth Differ* 1995;**6**:927-36.
102. Byrd JC, Shinn C, Willis CR, Flinn IW, Lehman T, Sausville E, Lucas D, Grever MR. UCN-01 induces cytotoxicity toward human CLL cells through a p53-independent mechanism. *Exp Hematol* 2001;**29**:703-8.
103. Kitada S, Zapata JM, Andreeff M, Reed JC. Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia. *Blood* 2000;**96**:393-7.
104. Harvey S, Decker R, Dai Y, Schaefer G, Tang L, Kramer L, Dent P, Grant S. Interactions between 2-fluoroadenine 9-beta-D-arabinofuranoside and the kinase inhibitor UCN-01 in human leukemia and lymphoma cells. *Clin Cancer Res* 2001;**7**:320-30.
105. Hsueh CT, Kelsen D, Schwartz GK. UCN-01 suppresses thymidylate synthase gene expression and enhances 5-fluorouracil-induced apoptosis in a sequence-dependent manner. *Clin Cancer Res* 1998;**4**:2201-6.
106. Sugiyama K, Akiyama T, Shimizu M, Tamaoki T, Courage C, Gescher A, Akinaga S. Decrease in susceptibility toward induction of apoptosis and alteration in G1 checkpoint function as determinants of resistance of human lung cancer cells against the antesignaling drug UCN-01 (7-Hydroxystaurosporine). *Cancer Res* 1999;**59**:4406-12.
107. Nieves-Neira W, Pommier Y. Apoptotic response to camptothecin and 7-hydroxystaurosporine (UCN-01) in the 8 human breast cancer cell lines of the NCI Anticancer Drug Screen: multifactorial relationships with topoisomerase I, protein kinase C, Bcl-2, p53, MDM-2 and caspase pathways. *Int J Cancer* 1999;**82**:396-404.
108. Bhoumik A, Ivanov V, Ronai Z. Activating transcription factor 2-derived peptides alter resistance of human tumor cell lines to ultraviolet irradiation and chemical treatment. *Clin Cancer Res* 2001;**7**:331-42.
109. Bredel M, Pollack IF, Freund JM, Rusnak J, Lazo JS. Protein kinase C inhibition by UCN-01 induces apoptosis in human glioma cells in a time-dependent fashion. *J Neurooncol* 1999;**41**:9-20.

110. Akiyama T, Sugiyama K, Shimizu M, Tamaoki T, Akinaga S. G1-checkpoint function including a cyclin-dependent kinase 2 regulatory pathway as potential determinant of 7-hydroxystaurosporine (UCN-01)-induced apoptosis and G1-phase accumulation. *Jpn J Cancer Res* 1999;**90**:1364-72.
111. Abe S, Kubota T, Otani Y, Furukawa T, Watanabe M, Kumai K, Akiyama T, Akinaga S, Kitajima M. UCN-01 (7-hydroxystaurosporine) inhibits in vivo growth of human cancer cells through selective perturbation of G1 phase checkpoint machinery. *Jpn J Cancer Res* 2001;**92**:537-45.
112. Akinaga S, Gomi K, Morimoto M, Tamaoki T, Okabe M. Antitumor activity of UCN-01, a selective inhibitor of protein kinase C, in murine and human tumor models. *Cancer Res* 1991;**51**:4888-92.
113. Kurata N, Kuwabara T, Tanii H, Fuse E, Akiyama T, Akinaga S, Kobayashi H, Yamaguchi K, Kobayashi S. Pharmacokinetics and pharmacodynamics of a novel protein kinase inhibitor, UCN-01. *Cancer Chemother Pharmacol* 1999;**44**:12-8.
114. Senderowicz AM, Sausville EA. Preclinical and clinical development of cyclin-dependent kinase modulators. *J Natl Cancer Inst* 2000;**92**:376-87.
115. Sausville EA, Arbuck SG, Messmann R, Headlee D, Bauer KS, Lush RM, Murgo A, Figg WD, Lahusen T, Jaken S, Jing X, Roberge M, Fuse E, et al. Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms. *J Clin Oncol* 2001;**19**:2319-33.
116. Wilson WH, Sorbara L, Figg WD, Mont EK, Sausville E, Warren KE, Balis FM, Bauer K, Raffeld M, Senderowicz AM, Monks A. Modulation of clinical drug resistance in a B cell lymphoma patient by the protein kinase inhibitor 7-hydroxystaurosporine: presentation of a novel therapeutic paradigm. *Clin Cancer Res* 2000;**6**:415-21.
117. Takahashi I, Saitoh Y, Yoshida M, Sano H, Nakano H, Morimoto M, Tamaoki T. UCN-01 and UCN-02, new selective inhibitors of protein kinase C. II. Purification, physico-chemical properties, structural determination and biological activities. *J Antibiot* 1989;**42**:571-6.

118. Harkin ST, Cohen GM, Gescher A. Modulation of apoptosis in rat thymocytes by analogs of staurosporine: lack of direct association with inhibition of protein kinase C. *Mol Pharmacol* 1998;**54**:663-70.
119. Wang SH, Phelps E, Utsugi S, Baker JR, Jr. Susceptibility of thyroid cancer cells to 7-hydroxystaurosporine-induced apoptosis correlates with Bcl-2 protein level. *Thyroid* 2001;**11**:725-31.
120. Sato S, Fujita N, Tsuruo T. Interference with PDK1-Akt survival signaling pathway by UCN-01 (7-hydroxystaurosporine). *Oncogene* 2002;**21**:1727-38.
121. Seynaeve CM, Stetler-Stevenson M, Sebers S, Kaur G, Sausville EA, Worland PJ. Cell cycle arrest and growth inhibition by the protein kinase antagonist UCN-01 in human breast carcinoma cells. *Cancer Res* 1993;**53**:2081-6.
122. Akinaga S, Nomura K, Gomi K, Okabe M. Effect of UCN-01, a selective inhibitor of protein kinase C, on the cell-cycle distribution of human epidermoid carcinoma, A431 cells. *Cancer Chemother Pharmacol* 1994;**33**:273-80.
123. Kawakami K, Futami H, Takahara J, Yamaguchi K. UCN-01, 7-hydroxyl-staurosporine, inhibits kinase activity of cyclin- dependent kinases and reduces the phosphorylation of the retinoblastoma susceptibility gene product in A549 human lung cancer cell line. *Biochem Biophys Res Commun* 1996;**219**:778-83.
124. Akiyama T, Yoshida T, Tsujita T, Shimizu M, Mizukami T, Okabe M, Akinaga S. G1 phase accumulation induced by UCN-01 is associated with dephosphorylation of Rb and CDK2 proteins as well as induction of CDK inhibitor p21/Cip1/WAF1/Sdi1 in p53-mutated human epidermoid carcinoma A431 cells. *Cancer Res* 1997;**57**:1495-501.
125. Courage C, Snowden R, Gescher A. Differential effects of staurosporine analogues on cell cycle, growth and viability in A549 cells. *Br J Cancer* 1996;**74**:1199-205.
126. Usuda J, Saijo N, Fukuoka K, Fukumoto H, Kuh HJ, Nakamura T, Koh Y, Suzuki T, Koizumi F, Tamura T, Kato H, Nishio K. Molecular determinants of UCN-01-induced growth inhibition in human lung cancer cells. *Int J Cancer* 2000;**85**:275-80.

127. Mack PC, Gandara DR, Bowen C, Edelman MJ, Paglieroni T, Schnier JB, Gelmann EP, Gumerlock PH. RB status as a determinant of response to UCN-01 in non-small cell lung carcinoma. *Clin Cancer Res* 1999;**5**:2596-604.
128. Cholody WM, Kosakowska-Cholody T, Michejda CJ. Bisimidazoacridones induce a potent cytostatic effect in colon tumor cells that sensitizes them to killing by UCN-01. *Cancer Chemother Pharmacol* 2001;**47**:241-9.
129. Chen X, Lowe M, Keyomarsi K. UCN-01-mediated G1 arrest in normal but not tumor breast cells is pRb- dependent and p53-independent. *Oncogene* 1999;**18**:5691-702.
130. Jiang H, Yang LY. Cell cycle checkpoint abrogator UCN-01 inhibits DNA repair: association with attenuation of the interaction of XPA and ERCC1 nucleotide excision repair proteins. *Cancer Res* 1999;**59**:4529-34.
131. Jones CB, Clements MK, Redkar A, Daoud SS. UCN-01 and camptothecin induce DNA double-strand breaks in p53 mutant tumor cells, but not in normal or p53 negative epithelial cells. *Int J Oncol* 2000;**17**:1043-51.
132. Vanhoefer U, Harstrick A, Achterrath W, Cao S, Seeber S, Rustum YM. Irinotecan in the treatment of colorectal cancer: clinical overview. *J Clin Oncol* 2001;**19**:1501-18.
133. Cunningham D, Pyrhonen S, James RD, Punt CJ, Hickish TF, Heikkila R, Johannesen TB, Starkhammar H, Topham CA, Awad L, Jacques C, Herait P. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. *Lancet* 1998;**352**:1413-8.
134. Aravantinos G, Skarlos DV, Kosmidis P, Georgoulas V, Sgouros I, Bafaloukos D, Androulakis N, Florou S, Fountzilas G. Irinotecan (CPT-11) in patients with advanced colorectal cancer previously treated with 5-fluorouracil-based chemotherapy. *Crit Rev Oncol Hematol* 1999;**32**:209-19.
135. Rothenberg ML. Efficacy and toxicity of irinotecan in patients with colorectal cancer. *Semin Oncol* 1998;**25**:39-46.
136. Takimoto CH, Kieffer LV, Kieffer ME, Arbuck SG, Wright J. DNA topoisomerase I poisons. *Cancer Chemother Biol Response Modif* 1999;**18**:81-124.

137. Jansen WJ, Zwart B, Hulscher ST, Giaccone G, Pinedo HM, Boven E. CPT-11 in human colon-cancer cell lines and xenografts: characterization of cellular sensitivity determinants. *Int J Cancer* 1997;**70**:335-40.
138. Kanzawa F, Sugimoto Y, Minato K, Kasahara K, Bungo M, Nakagawa K, Fujiwara Y, Liu LF, Saijo N. Establishment of a camptothecin analogue (CPT-11)-resistant cell line of human non-small cell lung cancer: characterization and mechanism of resistance. *Cancer Res* 1990;**50**:5919-24.
139. Lansiaux A, Bras-Goncalves RA, Rosty C, Laurent-Puig P, Poupon MF, Bailly C. Topoisomerase I-DNA covalent complexes in human colorectal cancer xenografts with different p53 and microsatellite instability status: relation with their sensitivity to CTP-11. *Anticancer Res* 2001;**21**:471-6.
140. Goldwasser F, Bae I, Valenti M, Torres K, Pommier Y. Topoisomerase I-related parameters and camptothecin activity in the colon carcinoma cell lines from the National Cancer Institute anticancer screen. *Cancer Res* 1995;**55**:2116-21.
141. van Ark-Otte J, Kedde MA, van der Vijgh WJ, Dingemans AM, Jansen WJ, Pinedo HM, Boven E, Giaccone G. Determinants of CPT-11 and SN-38 activities in human lung cancer cells. *Br J Cancer* 1998;**77**:2171-6.
142. Whitacre CM, Zborowska E, Willson JK, Berger NA. Detection of poly(ADP-ribose) polymerase cleavage in response to treatment with topoisomerase I inhibitors: a potential surrogate end point to assess treatment effectiveness. *Clin Cancer Res* 1999;**5**:665-72.
143. Guichard S, Hennebelle I, Bugat R, Canal P. Cellular interactions of 5-fluorouracil and the camptothecin analogue CPT-11 (irinotecan) in a human colorectal carcinoma cell line. *Biochem Pharmacol* 1998;**55**:667-76.
144. Xie X, Sasai K, Shibuya K, Tachiiri S, Nihei K, Ohnishi T, Hiraoka M. P53 status plays no role in radiosensitizing effects of SN-38, a camptothecin derivative. *Cancer Chemother Pharmacol* 2000;**45**:362-8.
145. McDonald AC, Brown R. Induction of p53-dependent and p53-independent cellular responses by topoisomerase 1 inhibitors. *Br J Cancer* 1998;**78**:745-51.

146. Gupta M, Fan S, Zhan Q, Kohn KW, O'Connor PM, Pommier Y. Inactivation of p53 increases the cytotoxicity of camptothecin in human colon HCT116 and breast MCF-7 cancer cells. *Clin Cancer Res* 1997;**3**:1653-60.
147. Bras-Goncalves RA, Rosty C, Laurent-Puig P, Soulie P, Dutrillaux B, Poupon MF. Sensitivity to CPT-11 of xenografted human colorectal cancers as a function of microsatellite instability and p53 status. *Br J Cancer* 2000;**82**:913-23.
148. Osaki S, Nakanishi Y, Takayama K, Pei XH, Ueno H, Hara N. Alteration of drug chemosensitivity caused by the adenovirus-mediated transfer of the wild-type p53 gene in human lung cancer cells. *Cancer Gene Ther* 2000;**7**:300-7.
149. Fallik D, Sabourin JC, Borrini F, Jacob S, Boige V, Praz F, Ducreux M. [Response of metastatic colorectal cancers to treatment with CPT11 (irinotecan): implications of the mismatched base repair system]. *Gastroenterol Clin Biol* 2000;**24**:917-22.
150. Jacob S, Aguado M, Fallik D, Praz F. The role of the DNA mismatch repair system in the cytotoxicity of the topoisomerase inhibitors camptothecin and etoposide to human colorectal cancer cells. *Cancer Res* 2001;**61**:6555-62.
151. Hausner P, Venzon DJ, Grogan L, Kirsch IR. The "comparative growth assay": examining the interplay of anti-cancer agents with cells carrying single gene alterations. *Neoplasia* 1999;**1**:356-67.
152. Fedier A, Schwarz VA, Walt H, Carpini RD, Haller U, Fink D. Resistance to topoisomerase poisons due to loss of DNA mismatch repair. *Int J Cancer* 2001;**93**:571-6.
153. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: a laboratory manual. *Laboratory Press Cold Spring Harbor* 1989.
154. Gayet J, Zhou XP, Duval A, Rolland S, Hoang JM, Cottu P, Hamelin R. Extensive characterization of genetic alterations in a series of human colorectal cancer cell lines. *Oncogene* 2001;**20**:5025-32.
155. Boyer JC, Umar A, Risinger JI, Lipford JR, Kane M, Yin S, Barrett JC, Kolodner RD, Kunkel TA. Microsatellite instability, mismatch repair deficiency, and genetic defects in human cancer cell lines. *Cancer Res* 1995;**55**:6063-70.

156. Ikeda M, Orimo H, Moriyama H, Nakajima E, Matsubara N, Mibu R, Tanaka N, Shimada T, Kimura A, Shimizu K. Close correlation between mutations of E2F4 and hMSH3 genes in colorectal cancers with microsatellite instability. *Cancer Res* 1998;**58**:594-8.
157. Koi M, Umar A, Chauhan DP, Cherian SP, Carethers JM, Kunkel TA, Boland CR. Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N'-nitro-N-nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation. *Cancer Res* 1994;**54**:4308-12.
158. Davis TW, Wilson-Van Patten C, Meyers M, Kunugi KA, Cuthill S, Reznikoff C, Garces C, Boland CR, Kinsella TJ, Fishel R, Boothman DA. Defective expression of the DNA mismatch repair protein, MLH1, alters G2-M cell cycle checkpoint arrest following ionizing radiation. *Cancer Res* 1998;**58**:767-78.
159. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, Sedivy JM, Kinzler KW, Vogelstein B. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. *Science* 1998;**282**:1497-501.
160. Arends MJ, Morris RG, Wyllie AH. Apoptosis. The role of the endonuclease. *Am J Pathol* 1990;**136**:593-608.
161. Ormerod MG. Investigating the relationship between the cell cycle and apoptosis using flow cytometry. *J Immunol Methods* 2002;**265**:73-80.
162. Grutter MG. Caspases: key players in programmed cell death. *Curr Opin Struct Biol* 2000;**10**:649-55.
163. Smulson ME, Simbulan-Rosenthal CM, Boulares AH, Yakovlev A, Stoica B, Iyer S, Luo R, Haddad B, Wang ZQ, Pang T, Jung M, Dritschilo A, Rosenthal DS. Roles of poly(ADP-ribosyl)ation and PARP in apoptosis, DNA repair, genomic stability and functions of p53 and E2F-1. *Adv Enzyme Regul* 2000;**40**:183-215.
164. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. *Br J Cancer* 1972;**26**:239-57.
165. Caulin C, Salvesen GS, Oshima RG. Caspase cleavage of keratin 18 and reorganization of intermediate filaments during epithelial cell apoptosis. *J Cell Biol* 1997;**138**:1379-94.

166. Chiu PM, Ngan YS, Khoo US, Cheung AN. Apoptotic activity in gestational trophoblastic disease correlates with clinical outcome: assessment by the caspase-related M30 CytoDeath antibody. *Histopathology* 2001;**38**:243-9.
167. Leers MP, Kolgen W, Bjorklund V, Bergman T, Tribbick G, Persson B, Bjorklund P, Ramaekers FC, Bjorklund B, Nap M, Jornvall H, Schutte B. Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis. *J Pathol* 1999;**187**:567-72.
168. Spadari S, Sala F, Pedrali-Noy G. Aphidicolin and eukaryotic DNA synthesis. *Adv Exp Med Biol* 1984;**179**:169-81.
169. Thyberg J, Moskalewski S. Role of microtubules in the organization of the Golgi complex. *Exp Cell Res* 1999;**246**:263-79.
170. Cliby WA, Roberts CJ, Cimprich KA, Stringer CM, Lamb JR, Schreiber SL, Friend SH. Overexpression of a kinase-inactive ATR protein causes sensitivity to DNA-damaging agents and defects in cell cycle checkpoints. *Embo J* 1998;**17**:159-69.
171. Blasina A, de Weyer IV, Laus MC, Luyten WH, Parker AE, McGowan CH. A human homologue of the checkpoint kinase Cds1 directly inhibits Cdc25 phosphatase. *Curr Biol* 1999;**9**:1-10.
172. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal Biochem* 1976;**72**:248-54.
173. Blagosklonny MV, Dixon SC, Robey R, Figg WD. Resistance to growth inhibitory and apoptotic effects of phorbol ester and UCN-01 in aggressive cancer cell lines. *Int J Oncol* 2001;**18**:697-704.
174. Shi Z, Azuma A, Sampath D, Li YX, Huang P, Plunkett W. S-Phase arrest by nucleoside analogues and abrogation of survival without cell cycle progression by 7-hydroxystaurosporine. *Cancer Res* 2001;**61**:1065-72.
175. Wilkinson MG, Millar JB. Control of the eukaryotic cell cycle by MAP kinase signaling pathways. *FASEB J* 2000;**14**:2147-57.
176. Tian H, Faje AT, Lee SL, Jorgensen TJ. Radiation-induced phosphorylation of Chk1 at S345 is associated with p53-dependent cell cycle arrest pathways. *Neoplasia* 2002;**4**:171-80.

177. Hsueh CT, Wu YC, Schwartz GK. UCN-01 suppresses E2F-1 mediated by ubiquitin-proteasome-dependent degradation. *Clin Cancer Res* 2001;**7**:669-74.
178. Kohn EA, Ruth ND, Brown MK, Livingstone M, Eastman A. Abrogation of the S phase DNA damage checkpoint results in S phase progression or premature mitosis depending on the concentration of 7-hydroxystaurosporine and the kinetics of Cdc25C activation. *J Biol Chem* 2002;**277**:26553-64.
179. Shimizu E, Zhao MR, Nakanishi H, Yamamoto A, Yoshida S, Takada M, Ogura T, Sone S. Differing effects of staurosporine and UCN-01 on RB protein phosphorylation and expression of lung cancer cell lines. *Oncology* 1996;**53**:494-504.
180. Dai Y, Yu C, Singh V, Tang L, Wang Z, McInistry R, Dent P, Grant S. Pharmacological inhibitors of the mitogen-activated protein kinase (MAPK) kinase/MAPK cascade interact synergistically with UCN-01 to induce mitochondrial dysfunction and apoptosis in human leukemia cells. *Cancer Res* 2001;**61**:5106-15.
181. McMasters RA, Wilbert TN, Jones KE, Pitlyk K, Saylor RL, Moyer MP, Chambers TC, Drake RR. Two-drug combinations that increase apoptosis and modulate bak and bcl-X(L) expression in human colon tumor cell lines transduced with herpes simplex virus thymidine kinase. *Cancer Gene Ther* 2000;**7**:563-73.
182. del Peso L, Gonzalez-Garcia M, Page C, Herrera R, Nunez G. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. *Science* 1997;**278**:687-9.
183. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. *Cell* 1997;**91**:231-41.
184. Scheid MP, Duronio V. Dissociation of cytokine-induced phosphorylation of Bad and activation of PKB/akt: involvement of MEK upstream of Bad phosphorylation. *Proc Natl Acad Sci U S A* 1998;**95**:7439-44.
185. Scheid MP, Schubert KM, Duronio V. Regulation of Bad phosphorylation and association with Bcl-x(L) by the MAPK/Erk kinase. *J Biol Chem* 1999;**274**:31108-13.
186. Tsuneoka M, Mekada E. Ras/MEK signaling suppresses Myc-dependent apoptosis in cells transformed by c-myc and activated ras. *Oncogene* 2000;**19**:115-23.

187. Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. *Science* 1995;**270**:1326-31.
188. Jarvis WD, Fornari FA, Jr., Tombes RM, Erukulla RK, Bittman R, Schwartz GK, Dent P, Grant S. Evidence for involvement of mitogen-activated protein kinase, rather than stress-activated protein kinase, in potentiation of 1-beta-D-arabinofuranosylcytosine-induced apoptosis by interruption of protein kinase C signaling. *Mol Pharmacol* 1998;**54**:844-56.
189. Persons DL, Yazlovitskaya EM, Pelling JC. Effect of extracellular signal-regulated kinase on p53 accumulation in response to cisplatin. *J Biol Chem* 2000;**275**:35778-85.
190. MacKeigan JP, Collins TS, Ting JP. MEK inhibition enhances paclitaxel-induced tumor apoptosis. *J Biol Chem* 2000;**275**:38953-6.
191. Lavoie JN, L'Allemain G, Brunet A, Muller R, Pouyssegur J. Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway. *J Biol Chem* 1996;**271**:20608-16.
192. Fukuoka K, Nishio K, Fukumoto H, Arioka H, Kurokawa H, Ishida T, Iwamoto Y, Tomonari A, Suzuki T, Usuda J, Narita N, Saijo N. Ectopic p16(ink4) expression enhances CPT-11-induced apoptosis through increased delay in S-phase progression in human non-small-cell-lung-cancer cells. *Int J Cancer* 2000;**86**:197-203.
193. Pavillard V, Formento P, Rostagno P, Formento JL, Fischel JL, Francoual M, Etienne MC, Milano G. Combination of irinotecan (CPT11) and 5-fluorouracil with an analysis of cellular determinants of drug activity. *Biochem Pharmacol* 1998;**56**:1315-22.
194. Bates S, Ryan KM, Phillips AC, Vousden KH. Cell cycle arrest and DNA endoreduplication following p21Waf1/Cip1 expression. *Oncogene* 1998;**17**:1691-703.
195. Hirose Y, Berger MS, Pieper RO. p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells. *Cancer Res* 2001;**61**:1957-63.
196. te Poele RH, Okorokov AL, Jardine L, Cummings J, Joel SP. DNA damage is able to induce senescence in tumor cells in vitro and in vivo. *Cancer Res* 2002;**62**:1876-83.

197. Merritt AJ, Allen TD, Potten CS, Hickman JA. Apoptosis in small intestinal epithelial from p53-null mice: evidence for a delayed, p53-independent G2/M-associated cell death after gamma-irradiation. *Oncogene* 1997;**14**:2759-66.
198. Lock RB, Stribinskiene L. Dual modes of death induced by etoposide in human epithelial tumor cells allow Bcl-2 to inhibit apoptosis without affecting clonogenic survival. *Cancer Res* 1996;**56**:4006-12.
199. te Poele RH, Joel SP. Schedule-dependent cytotoxicity of SN-38 in p53 wild-type and mutant colon adenocarcinoma cell lines. *Br J Cancer* 1999;**81**:1285-93.
200. Motwani M, Jung C, Sirotiak FM, She Y, Shah MA, Gonen M, Schwartz GK. Augmentation of apoptosis and tumor regression by flavopiridol in the presence of CPT-11 in HCT116 colon cancer monolayers and xenografts. *Clin Cancer Res* 2001;**7**:4209-19.
201. Shao RG, Cao CX, Nieves-Neira W, Dimanche-Boitrel MT, Solary E, Pommier Y. Activation of the Fas pathway independently of Fas ligand during apoptosis induced by camptothecin in p53 mutant human colon carcinoma cells. *Oncogene* 2001;**20**:1852-9.
202. Ohmori T, Podack ER, Nishio K, Takahashi M, Miyahara Y, Takeda Y, Kubota N, Funayama Y, Ogasawara H, Ohira T, Ohta S, Saijo N. Apoptosis of lung cancer cells caused by some anti-cancer agents (MMC, CPT-11, ADM) is inhibited by bcl-2. *Biochem Biophys Res Commun* 1993;**192**:30-6.
203. Elliott B, Jasin M. Repair of double-strand breaks by homologous recombination in mismatch repair-defective mammalian cells. *Mol Cell Biol* 2001;**21**:2671-82.